Objective: It has long been known that hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) broadly reduce cardiovascular events in patients with peripheral vascular disease. It was the goal of this study to determine whether there is an association between statin therapy and primary patency after stenting of superficial femoral and popliteal arteries.
The use of statins to reduce coronary vascular events is well established. [1] [2] [3] [4] These findings, combined with the benefits of other lipid-lowering agents, propelled the American Heart Association (AHA) and American College of Cardiology (ACC) to incorporate risk reduction guidelines of low-density lipoprotein (LDL) levels <100 mg/dL for patients with coronary artery disease. 4, 5 In light of these findings, the benefits of statin therapy in peripheral arterial disease (PAD) have also been investigated. 6 In the randomized Scandinavian Simvastatin Survival Study (4S), statins significantly reduced the incidence of new intermittent claudication from 3.6% to 2.3% during a median period of 5.4 years in patients with known cardiovascular disease. 7 In addition, both simvastatin and atorvastatin have been shown to improve pain-free walking time in patients with known peripheral vascular disease. 8, 9 Given the benefit of lipidlowering agents in the treatment of PAD, the AHA and ACC have expanded the guidelines for risk reduction of LDL levels <100 mg/dL to include patients with PAD. 6, 10 In higher risk patients, a target LDL level of <70 mg/dL is recommended. 6 Statin therapy has also been shown to improve outcomes related to major peripheral vascular surgery. Notably, this includes a reduction in major adverse cardiovascular events after vascular surgery, 11 improved patency after infrainguinal bypass surgery, 12 and improved outcomes after endovascular aortic aneurysm repair 13 and carotid artery stenting. 14 Despite this evidence and the recommendations of the AHA and ACC, optimal medical management in PAD has repeatedly been shown to be underused. [15] [16] [17] [18] The effect of periprocedural statin therapy in patients undergoing peripheral endovascular treatment is less clear. Although statins have been shown in some studies to be associated with superior clinical outcomes after endovascular treatment of critical limb ischemia (CLI), 15 their role in less severe PAD, including patients with claudication, remains unknown. In addition, these studies contained patients undergoing a variety of percutaneous interventions. The purpose of this study was to investigate the effects of statin therapy in patients suffering from both claudication and CLI specifically undergoing primary stenting of either the superficial femoral artery (SFA), popliteal artery (PA), or both.
METHODS
After approval was obtained from the Institutional Review Board, the records of all patients undergoing primary nitinol stenting of the SFA or PA during a 10-year period were reviewed. Because of the retrospective nature of the study, a waiver for informed consent was granted by the Institutional Review Board, and informed consent was not obtained before inclusion in the study. All procedures included in this study were performed at a single institution and by or under the direct supervision of one vascular surgeon (S.K.). During the study period, diseased segments involving the SFA and all segments of the PA were primarily treated with the same technique, using exclusively self-expanding nitinol stents after balloon angioplasty. As described previously, 19, 20 no attempts were made to perform percutaneous intervention on patients with orificial or total occlusion of the SFA, PA, and proximal tibial arteries. These patients were preferentially treated with bypass surgery. The study excluded patients who were lost to follow-up before a repeated arterial duplex ultrasound scan was performed after stent placement and those who were taking lipid-lowering agents other than statins at the time of intervention. Data collected included demographics of the patients, comorbidities, and use of a statin drug at the time of intervention. Indication for procedure, location of lesion, and lesion severity were recorded on a per-limb basis. Statin compliance was monitored by reviewing the records of the study patients' primary care providers, which in large part included selfreported current medication regimens. Patients were considered to have been compliant with statin therapy if they continued statin therapy from the time of stent placement until last recorded follow-up. Lesion severity was characterized using the TransAtlantic Inter-Society Consensus (TASC II) classification. 21 To reduce previously described interobserver variability with TASC II classification, 22 each angiogram was reviewed separately by at least two of the authors. Discrepancies in TASC II classification were resolved on joint review of the angiograms in question. For the purpose of data analysis, TASC A and B lesions were grouped together, as were TASC C and D lesions. TASC classifications were not evaluated on an individual basis to maintain more limbs in both the TASC A/B and TASC C/D groups as well as to allow expected interobserver bias. All of the procedures were performed in an angiography suite with fixed imaging. Our methods of intervention have previously been described. 19, 20 Stents were chosen on the basis of supply and the surgeon''s preference. Patients received clopidogrel (300 mg) and aspirin (325 mg) before their procedures. All patients received 5000 units of heparin before percutaneous transluminal angioplasty and stent placement. Anticoagulation was not reversed at the end of the procedure. After the intervention, all patients received a minimum of a 30-day course of clopidogrel (75 mg daily) and aspirin (81 mg). Successful intervention was defined as an angiographic residual stenosis <30% in the treated vessel. Patients underwent arterial duplex ultrasound scans at 30 days after the intervention and at 6-month intervals thereafter. Loss of primary patency was defined as stent occlusion or development of a $70% stenosis in the stented segment. A 70% stenosis was said to be present when a peak systolic velocity of at least 200 cm/s and a 3:1 velocity ratio were seen across the lesion, which in our vascular laboratory correlates with a hemodynamically significant stenosis of 70% on angiography. 23 We analyzed 308 interventions consisting of 250 patients. To create an independent sample, a single intervention for each patient among those with multiple interventions was taken by simple random sampling methods, yielding an analytic data set of 250 distinct interventions or patients. The differences in characteristics of the patients, comorbidities, and characteristics of the lesions between the cohorts of statin users and nonstatin users were examined by Fisher exact test for categorical variables and t-test for continuous variables (age). Recommendation: This study suggests that statin use may improve primary patency of stents of some lesions in the femoral and popliteal arteries.
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Age was additionally categorized by quartiles and examined for differences in statin therapy by Fisher exact test. Kaplan-Meier analysis and a log-rank test were performed to assess differences in survival time. Survival was defined as the time from randomization until loss of primary patency. Data for patients who did not experience loss of primary patency were censored at the date of the last follow-up visit at which patency was demonstrated.
The association of statin use with the risk of loss of patency was estimated using the Cox proportional hazards model, controlling for the patient's characteristics and comorbidities, to determine the hazard ratio (HR) of the risk of patency loss for statin users compared with nonstatin users. Because covariates were not specified a priori, potential confounders were evaluated on the basis of a change in the statin HR estimate of $15%. Potential confounders included any of the patients' characteristics or comorbidities univariately significantly associated with statin therapy or survival. Lack of multicollinearity among all potential covariates was verified by the calculation of variance inflation factors. Hyperlipidemia was not considered a confounder because of its indication in statin therapy prescription. An interaction term between statin use and TASC classification group was tested, and results for the multivariate model were reported as stratified by TASC group. The proportional hazards assumption was investigated both graphically and by adding an interaction with time to the model and was not deemed to be in violation. Differences with a P # .05 were considered significant. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). Post hoc power analysis was done using PASS (PASS 14 Power Analysis and Sample Size Software; NCSS LLC, Kaysville, Utah).
RESULTS
Between July 2004 and July 2014, there were 382 primary SFA or PA stenting procedures performed. The study excluded 39 patients who underwent 44 procedures who were lost to follow-up as well as 30 patients who underwent 32 procedures who were using lipidlowering agents other than statins, leaving 308 interventions in 250 patients for analysis. Using random sampling as described before, only one intervention per patient was included for further analysis, yielding 250 interventions for inclusion in this study. Of these patients, 112 (45%) were men and 138 (55%) were women. Of the 250 included patients, 131 (52.4%) were receiving statin therapy at the time of the procedure. The mean followup time was 16.5 (615.0) months for statin users and 13.1 (612.9) months for nonstatin users; the median followup time was 12 months for statin users and 8.5 months for nonstatin users. At the time of most recent followup by records obtained from the patients' primary care providers, statin compliance was found to be 87% (mean follow-up, 723 6 647 days).
As shown in Table I , patients in the statin group tended to be younger (73.8 vs 78.1 years). In addition, the statin group had significantly more cardiovascular risk factors. This included higher rates of coronary artery disease, chronic kidney disease, diabetes, history of myocardial infarction, and history of coronary artery bypass (P < .04 for each). In contrast, patients who were receiving statin therapy were less likely to have a history of cerebrovascular accident compared with controls (P ¼ .03). The groups did not differ significantly with regard to race, smoking history, congestive heart failure, hypertension, chronic pulmonary disease, or dialysis dependency.
Procedure indications, lesion location, and lesion severity are listed in Table II . Of the 250 procedures performed, 137 (55%) were done for claudication and 113 (45%) were done for CLI. A higher proportion of statin users underwent stent placement for claudication compared with controls (61.1% vs 47.9%), whereas a higher proportion of controls underwent stent placement for tissue loss compared with statin users (35.5% vs 21.4%). There were 137 isolated SFA lesions and 45 isolated PA lesions, and 68 lesions involved both the SFA and PA. A total of 165 lesions were classified as TASC A/B and 85 were classified as TASC C/D. A Kaplan-Meier analysis with the log-rank test was performed to assess the influence of statin therapy on the time to loss of patency (Figs 1-3) . Of the 250 patients, 96 patients experienced stent failure during the study follow-up, of whom 50 were statin users and 46 were controls. In the statin group, Kaplan-Meier estimates of the rates of patency were 79.9% at 12 months, 55.3% at 24 months, and 40.2% at 36 months compared with rates of 68.2%, 49.2%, and 28.0%, respectively, in the control group (Table III ). An unadjusted Kaplan-Meier analysis indicated that patients in the statin group have better survival than patients who do not use statins, although the difference did not reach significance (logrank, P ¼ .18). When stratified by TASC classification, the statin therapy cohort demonstrated a trend for better survival prognosis compared with controls for TASC A/B patients (log-rank, P ¼ .06), whereas no difference was observed for TASC C/D patients (log-rank, P ¼ .53).
Univariate Cox regression analysis showed that the risk of patency loss was significantly lower for patients who did not have a limb amputation during the study (P ¼ .03) and for patients in the TASC A/B classification group (P < .001; Table IV ). In a Cox regression model adjusting for any cardiac comorbidities, indications, and TASC category, a significant interaction between statin use and TASC category was observed at P ¼ .03 (Table V) . For patients who were in the TASC A/B classification group, the risk of patency loss was marginally lower for statin users compared with the control group (HR, 0.57; 95% confidence interval [CI], 0.32-1.02; P ¼ .06) after adjusting for indication and any cardiac comorbidities (Table VI) . No significant difference in risk was observed for patients who were in the TASC C/D group (HR, 1.54; 95% CI, 0.81-2.90; P ¼ .19). Post hoc power analysis showed that on the basis of a sample size of 250 patients with 131 treatment and 119 control patients and an average stent failure probability of 38% and 39% for the treatment and control groups, respectively, we had 80% power to detect an HR of .564 at a two-sided a level of .05.
DISCUSSION
The consequences of atherosclerosis remain a significant burden to public health. Cardiovascular disease remains the leading cause of death in the United States and is responsible for 17% of national health expenditures. 24, 25 In addition, it is estimated that 7 million individuals of the adult population of the United States older than 40 years will suffer from PAD by the year 2020. 26 The prevalence and cost of cardiovascular disease and PAD provide compelling impetus for reduction During the last decade, an endovascular approach has become a first-line treatment of both femoral and popliteal lesions. Advantages of catheter-based procedures have been well chronicled and include decreased morbidity, shortened hospital stays, and acceptance by the patients. Disadvantages have traditionally included relatively low rates of primary patency and the necessity of numerous interventions to achieve a lasting result. 20 As a result, improvement in primary patency rates remains an important area of interest for those performing these endovascular procedures.
The optimal medical management to maintain patency in patients with PAD having undergone femoropopliteal stent placement remains unclear. It is known that antiplatelet agents broadly reduce the risk of cardiovascular events in this population, 29 but their ability to improve endovascular procedure-specific and limbrelated outcomes in these patients has not been reliably reproduced. 30, 31 Investigations into the ability of longterm anticoagulants to provide additional benefit yielded no further cardiovascular risk reduction, 32 and their ability to improve stent patency and limb salvage is similarly unproven. More recently, drug-coated angioplasty balloons and drug-eluting stents have shown promise in improving patency rates of femoropopliteal lesions, although head-to-head comparisons have yet to yield clear-cut superiority of one technique over the other. 33, 34 To date, there has been limited investigation into the effect of lipid-lowering agents, specifically statins, on the rates of primary patency of peripheral endovascular interventions. Aiello et al 15 investigated the association of statins and clinical outcomes after endovascular intervention for CLI across all lower extremity levels and found improved overall survival, primary and secondary patency, and limb salvage rates in patients who were receiving statin therapy as opposed to those who did not. On the contrary, Fernandez et al 35 underwent tibial endovascular interventions. This discrepancy may be due to the fact that one of the studies was limited to tibial interventions, whereas the other was not. Our study failed to find a statistically significant association between periprocedural statins and stent patency in patients undergoing primary stenting of the SFA or PA. This is in contradistinction to the study of Aiello, which included angioplasty alone, atherectomy, and tibial interventions. Our study is much more specific in its focus, and this may well have accounted for the lack of benefit that we observed. This is similar to the study of Suckow et al, 36 who found no improvement in limbrelated outcomes and statin therapy in the Vascular Study Group of New England registry. In our study, 52% of patients were receiving statin therapy at the time of intervention. Although clearly not optimal, it demonstrates a higher percentage of this population of patients taking statins than has previously been reported. 15, 17, 37 During the period of review, much of the research on statin therapy and its benefits in PAD had yet to be published, and this likely accounts for the low percentage of patients taking statins in these study groups. Our comparatively higher percentage of patients taking statins may reflect an overall increased awareness of the benefit of this therapy in this population of patients during the last decade, given that our review was carried out during a 10-year period, ending in 2014. Our statin group was younger and had a higher prevalence of coronary artery disease, chronic kidney disease, diabetes, history of myocardial infarction, and history of coronary artery bypass. This echoes findings of similar-type studies looking at effects of statins in a population of patients with significantly more medical comorbidities. 15, 38 In multivariate analysis, none of these factors were associated with loss of primary patency, making it unlikely that they biased our primary outcome measure. In addition, our analysis of statin compliance was not reliably recorded at the time of most recent evaluation of patency, which limits our ability to determine whether there was an association between stopping statin therapy after stents had been placed and patency. Because of the retrospective nature of our study, we were unable to determine whether patients' optimal lipid levels were achieved, and this certainly is an inherent limitation of the study design. Regardless, there continues to be compelling data supporting the use of statin drugs to combat atherosclerosis as a result of their pleiotropic effects in addition to their lipid-lowering properties.
39,40
Interestingly, we noted a trend toward improved primary patency in the statin cohort with less severe disease (TASC A/B). To our knowledge, an investigation into the association of statin use with primary patency stratified for lesion severity has not previously been undertaken. The trend we observed toward an association between statin use and primary patency of less severe lesions is one that could be of clinical importance and warrants further investigation in subsequent studies. 
CONCLUSIONS
Although the existing literature certainly supports the use of statins in reducing cardiovascular morbidity and mortality in patients with peripheral vascular disease, there is not an association of these drugs with improved primary patency in taking into account lesions of all severity. However, when limbs are stratified for severity, patients with TASC A/B disease demonstrated a trend toward a significant association between statin use and improved primary patency. This finding was not seen in more severe disease (TASC C/D). As a result, these patients should be prescribed statin therapy unless it is contraindicated, but not with the expectation that it will improve stent-specific outcomes in those with severe disease. 
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